RET drugs for Non-Small Cell Lung Cancer
5 tracked RET drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the RET page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 42 Phase 1/21 preclinical / unstaged
Head-to-head evidence: Lunbotinib vs Pralsetinib · Lunbotinib vs Selpercatinib · Pralsetinib vs SNH-118110 · Pralsetinib vs Selpercatinib · Pralsetinib vs Vepafestinib · Selpercatinib vs SNH-118110